Delving into the Latest Updates on Canget BioTekpharma LLC with Synapse

Overview

Tags

Neoplasms

Endocrinology and Metabolic Disease

Urogenital Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	14
Endocrinology and Metabolic Disease	9
Immune System Diseases	2
Hemic and Lymphatic Diseases	2
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	14

Top 5 Target	Count

survivin(Baculoviral IAP repeat-containing protein 5)	1

Survivin (also named BIRC5) is a well-known cancer therapeutic target. Since its discovery more than two decades ago, the use of survivin as a target for cancer therapeutics has remained a central goal of survivin studies in the cancer field. Many studies have provided intriguing insight into survivin's functional role in cancers, thus providing promise for survivin as a cancer therapeutic target. Despite this, moving survivin-targeting agents into and through the clinic remains a challenge. In order to address this challenge, we may need to rethink current strategies in order to develop a new mindset for targeting survivin. In this Review, we will first summarize the current survivin mechanistic studies, and then review the status of survivin cancer therapeutics, which is classified into five categories: (i) survivin-partner protein interaction inhibitors, (ii) survivin homodimerization inhibitors, (iii) survivin gene transcription inhibitors, (iv) survivin mRNA inhibitors and (v) survivin immunotherapy. We will then provide our opinions on cancer therapeutics using survivin as a target, with the goal of stimulating discussion that might facilitate translational research for discovering improved strategies and/or more effective anticancer agents that target survivin for cancer therapy.

International Journal of Molecular Sciences

Molecular Glues: Capable Protein-Binding Small Molecules That Can Change Protein–Protein Interactions and Interactomes for the Potential Treatment of Human Cancer and Neurodegenerative Diseases

Review

Author: Ling, Xiang ; Li, Fengzhi ; Aljahdali, Ieman A M

Molecular glue (MG) compounds are a type of unique small molecule that can change the protein–protein interactions (PPIs) and interactomes by degrading, stabilizing, or activating the target protein after their binging. These small-molecule MGs are gradually being recognized for their potential application in treating human diseases, including cancer. Evidence suggests that small-molecule MG compounds could essentially target any proteins, which play critical roles in human disease etiology, where many of these protein targets were previously considered undruggable. Intriguingly, most MG compounds with high efficacy for cancer treatment can glue on and control multiple key protein targets. On the other hand, a single key protein target can also be glued by multiple MG compounds with distinct chemical structures. The high flexibility of MG–protein interaction profiles provides rich soil for the growth and development of small-molecule MG compounds that can be used as molecular tools to assist in unraveling disease mechanisms, and they can also facilitate drug development for the treatment of human disease, especially human cancer. In this review, we elucidate this concept by using various types of small-molecule MG compounds and their corresponding protein targets that have been documented in the literature.

American Journal of Cancer Research

Synergistic effect of allyl isothiocyanate (AITC) on cisplatin efficacy in vitro and in vivo

Author: He, Xiang ; Chan, Daniel C. F. ; Cao, Felicia ; Li, Fengzhi ; Zhang, Yuesheng ; Cao, Shousong ; Ling, Xiang ; Kim, Hak-Ryul ; Westover, David

Although in vitro studies have shown that isothiocyanates (ITCs) can synergistically sensitize cancer cells to cisplatin treatment, the underlying mechanisms have not been well defined, and there are no in vivo demonstrations of this synergy.Here, we report the in vitro and in vivo data for the combination of allyl isothiocyanate (AITC), one of the most common naturally occurring ITCs, with cisplatin.Our study revealed that cisplatin and AITC combination synergistically inhibits cancer cell growth and colony formation, and enhances apoptosis in association with the downregulation of antiapoptotic proteins Bcl-2 and survivin.Importantly, the in vivo combination treatment suppresses human tumor growth in animal models without observable increases in toxicity (body weight loss) in comparison with single agent treatment.Furthermore, our data revealed that addition of AITC to cisplatin treatment changes the profile of G2/M arrest (e.g. increase in M phase cell number) and significantly extends the duration of G2/M arrest in comparison with cisplatin treatment alone.To explore the underlying mechanism, we found that AITC treatment rapidly depletes b-tubulin.Combination of AITC and cisplatin inhibits the expression of G2/M checkpointrelevant proteins including CDC2, cyclin B1 and CDC25.Together, our findings reveal a novel mechanism for AITC enhancing cisplatin efficacy and provides the first in vivo evidence to support ITCs as potential candidates for developing new regimens to overcome platinum resistance.

100 Deals associated with Canget BioTekpharma LLC

Login to view more data

100 Translational Medicine associated with Canget BioTekpharma LLC

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

12

2

Preclinical

Other

6

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

FL-118 ( survivin )	Soft Tissue Sarcoma More	Preclinical
FL496	Retinoblastoma More	Preclinical
WSX2	Colonic Cancer More	Discovery
JT-15	Colonic Cancer More	Discovery
FL7728	Ovarian Cancer More	Discovery